Company profile: Stokes Bio
1.1 - Company Overview
Company description
- Provider of microfluidic technology and systems for genetic analysis, developing and distributing microfluidics solutions to clients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Stokes Bio
Vanadis Diagnostics
HQ: Sweden
Website
- Description: Provider of a novel non-invasive prenatal testing (NIPT) solution in development based on digital analysis of cell-free DNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanadis Diagnostics company profile →
TriLink BioTechnologies
HQ: United States
Website
- Description: Provider of custom oligonucleotides, modified nucleotides, long RNA and mRNA for the diagnostic, therapeutic and OEM markets, offering mRNA synthesis services and GMP mRNA manufacturing, CleanCap capping solutions, custom NTPs, specialty oligo synthesis, and in-house analytical method development and testing; also supplies CleanAmp PCR products and phosphoramidites.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TriLink BioTechnologies company profile →
Tango Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cancer therapies leveraging synthetic lethality, including TNG908 and TNG462, PRMT5 inhibitors for MTAP-deleted cancers; TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers; and TNG348, a USP1 inhibitor for BRCA1/2-mutant and other HRD+ cancers, all in Phase 1/2 trials. Also provides a CRISPR-based functional genomics platform to identify synthetic lethal targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tango Therapeutics company profile →
Ultima Genomics
HQ: United States
Website
- Description: Provider of a low-cost sequencing platform and related workflows, including the UG 100™ high-throughput system using a 200mm open silicon wafer with built-in automation; ppmSeq™ for rare event detection at one part per million for liquid biopsies and MRD; large-scale single-cell and spatial sequencing workflows; RNA-Seq for gene expression and isoform analysis; and genome-wide methylation sequencing compatible with standard tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultima Genomics company profile →
MultiVir
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiVir company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Stokes Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Stokes Bio
2.2 - Growth funds investing in similar companies to Stokes Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Stokes Bio
4.2 - Public trading comparable groups for Stokes Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →